An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications

(2020) Wook Jin   Cancers

Repurposing EGFR inhibitor utility in colorectal cancer in mutant APC and TP53 subpopulations

(2019) Mingli Yang et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer

(2019) Tianzuo Zhan et al.   Nature Communications

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC

(2019) Man Yuan et al.   Frontiers in Oncology

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC

(2019) Thomas B. Davis et al.   Oncotarget

Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells

(2018) Fiona Simpkins et al.   CLINICAL CANCER RESEARCH

Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity

(2018) Guanhua Rao et al.   EUROPEAN JOURNAL OF CANCER

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer

(2018) Ryan B. Corcoran et al.   Cancer Discovery

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation

(2018) Thomas B. Davis et al.   Scientific Reports

Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer

(2017) Guangming Chen et al.   MOLECULAR CANCER THERAPEUTICS

Cancer stem cells revisited

(2017) Eduard Batlle et al.   NATURE MEDICINE

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

(2017) Tsukasa Shibue et al.   Nature Reviews Clinical Oncology

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

(2017) Robin M.J.M. van Geel et al.   Cancer Discovery

CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models

(2017) Peter W. Eide et al.   Scientific Reports

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

(2017) Grace R. Anderson et al.   Cell Reports

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

(2016) Bernard Omolo et al.   BMC Medical Genomics

EMT: 2016

(2016) M. Angela Nieto et al.   CELL

Transcriptional signature induced by a metastasis-promoting c-Src mutant in a human breast cell line

(2016) Felix Broecker et al.   FEBS Journal

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

(2016) Michael J. Schell et al.   Nature Communications

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome

(2015) M. J. Schell et al.   CLINICAL CANCER RESEARCH

The consensus molecular subtypes of colorectal cancer

(2015) Justin Guinney et al.   NATURE MEDICINE

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

(2015) Enzo Medico et al.   Nature Communications

Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling

(2014) Andreas Herbst et al.   BMC GENOMICS

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

EMT is the dominant program in human colon cancer

(2013) Andre Loboda et al.   BMC Medical Genomics

Origins of Metastatic Traits

(2013) Sakari Vanharanta et al.   CANCER CELL

Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer

(2013) Beatrix Elsberger   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

(2013) Laetitia Marisa et al.   PLOS MEDICINE

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion

(2012) J Ferguson et al.   ONCOGENE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Implementing Personalized Medicine in a Cancer Center

(2011) David A. Fenstermacher et al.   CANCER JOURNAL

The Intestinal Stem Cell Signature Identifies Colorectal Cancer Stem Cells and Predicts Disease Relapse

(2011) Anna Merlos-Suárez et al.   Cell Stem Cell

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

(2010) Andrey Loboda et al.   BMC Medical Genomics

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

(2010) J. R. Dry et al.   CANCER RESEARCH

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

(2010) J. J. Arcaroli et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

TWIST1 Overexpression is Associated with Nodal Invasion and Male Sex in Primary Colorectal Cancer

(2008) Fátima Valdés-Mora et al.   ANNALS OF SURGICAL ONCOLOGY